"Designing Growth Strategies is in our DNA"
Region : Global | Published Date: Upcoming | Report ID: FBI101274| Status : Pipeline
Cirrhosis refers to a medical condition which occurs in the liver, which causes the gradual replacement of healthy liver cells by scar tissue in individuals. Cirrhosis generally occurs over a long period of time and can be attributed to infections and alcohol addiction. In most of the instances, the damage to the liver cannot be reversed, but if diagnosed early there are numerous treatment options that can keep the associated problems in check. Cirrhosis occurs when the liver is repeated damaged, leading it to cause tough scar tissue and due to the buildup of the scar tissue, the liver no longer functions properly.
Some of the common symptoms associated with cirrhosis include fatigue and weakness, weight loss, lack of appetite and nausea. One of the most common diagnostic methods for cirrhosis includes the conduction of a blood test, so the cirrhosis can be diagnosed at a certain stage. Some of the treatment options for cirrhosis include lifestyle changes such as a low sodium diet and complete stoppage of alcohol consumption, medications and in advanced stages, liver transplantation. Some of the medications for the cirrhosis include blood pressure medications, vitamins, antibiotics, and vaccinations.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for cirrhosis. For instance; BMS-986036, which is being studied by Bristol-Myers Squibb Company, is currently in phase-2 clinical trials for a study of BMS-986036 in subjects with non-alcoholic steatohepatitis (NASH).
To get details on market share, speak to our analyst
At present, around 60% of the pipeline candidates for cirrhosis are in the phase-2 and phase-3 stage combined. Majority of the studies are sponsored by industry.
The report on ‘Cirrhosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Cirrhosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Cirrhosis.
The report on ‘Cirrhosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.